These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22587385)

  • 1. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Guérin A; Wu EQ; Bollu VK; Williams D; Guo A; de Leon DP; Quintas-Cardama A
    J Med Econ; 2013; 16(1):125-33. PubMed ID: 22587385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
    Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
    Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    J Med Econ; 2014 Feb; 17(2):89-98. PubMed ID: 24188054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
    McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
    Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
    Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
    Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
    Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
    J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
    Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
    Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
    Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
    Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
    Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
    McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
    Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An association between Dasatinib, elevated left atrial pressure and pleural effusion.
    Tan S; Baggio D; Porch K; Nerlekar N; Shortt J; Ko B
    Int J Cardiol; 2024 Sep; 410():132216. PubMed ID: 38821121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
    Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2018 Oct; 21(10):1036-1040. PubMed ID: 30071761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of survival gains in chronic myeloid leukemia.
    Yin W; Penrod JR; Maclean R; Lakdawalla DN; Philipson T
    Am J Manag Care; 2012 Nov; 18(11 Suppl):S257-64. PubMed ID: 23327457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.